Article PDF first page preview

First page of Investigation of Recognition Areas by Explainable AI for Colonoscopy Images of Irritable Bowel Syndrome

Introduction and Aim: Irritable Bowel Syndrome (IBS) is a condition in which gastroenterological endoscopists cannot detect anomalies using colonoscopy, yet an artificial intelligence (AI) developed for IBS colonoscopy images has been able to distinguish between IBS and healthy individuals with high accuracy. However, it was unclear in which areas the AI identified as abnormal. The aim of this study was to elucidate how AI identifies regions typical of IBS by constructing an additional Explainable AI (XAI). Methods: Colonoscopy images of healthy individuals, patients with constipation-predominant IBS, and patients with diarrhea-predominant IBS, which are available in a repository (https://doi.org/10.5061/dryad.9s4mw6mkp), were used. After setting up a Python environment on a local PC, the XAI models for the three groups were developed. Images not used in the AI construction were then evaluated using XAI. XAI-generated images were independently assessed by two evaluators, HM and KS, to record and reconcile the characteristic differences among the three groups. Results: Images correctly identified as those of healthy individuals by XAI were evaluated as characteristics over the entire image. By contrast, for IBS, only parts of the images were evaluated as characteristic regions. For diarrhea-predominant IBS, regions characterized by clear vascular boundaries, homogeneity or erythematous tones, or narrow and somewhat dark-appearing sections of the intestinal tract were identified. For constipation-predominant IBS, regions characterized by unclear vascular boundaries, faded tones, or dark sections where the end was not visible were identified. Conclusion: An XAI for IBS was collaboratively developed by endoscopists and clinical engineers, enabling the visualization of regions characteristic of IBS and healthy individuals. The real-time display of XAI is expected to further advance the elucidation of IBS pathophysiology.

Journal Section:
To the Point Article
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial